Underrepresentation of the black community in clinical trials is a dangerous problem. Whether seeking to overcome persistent hesitancy over a Covid-19 vaccine or finding a moonshot cancer solution, finding outcomes for diverse populations must be a priority regardless of healthcare needs. We can work together to restore trust in clinical trials and deliver critical, inclusive, life-saving healthcare solutions to the black community by addressing the three vital elements needed to address this dangerous problem: improving education, accessing clinical trials, and advancing clinical trials Diversity of the workforce.
Imagine your loved one is taking an approved medication for a serious, life-threatening condition, but you are not sure if it will work, or worse, if it will make their The disease went down because it wasn’t tested on enough people like you. This is the reality for many in the black community today.Black representation in clinical trials supporting 371 drugs and biologics approved between 2007 and 2017 was 65% lower than census level and disease population, according to Tufts Center for Drug Development and Research.
A recent ad campaign aimed at educating diverse populations about the importance of participating in clinical research says it best:”Disease does not discriminate. The event identified key factors in creating trial diversity leading to the discovery of effective treatments for all populations. In one oncology example, Black Breast Cancer Coalition, Touch, Recently shared that the physiology of black women is not taken into account in clinical trial studies. According to the American Cancer Society, to start addressing mortality statistics, we must include black women in breast cancer research, because black women under age 35 are twice as likely to develop breast cancer as white women and die at the same rate as white women three times. Ongoing work at Touch shows that a lack of education, opportunity and trust can lead to a lack of participation in trials that unnecessarily put Black women’s lives at greater risk.
The pandemic has revealed our health disparities in America, and I have experienced firsthand the difficult moral dilemma that many in the black community are going through with vaccine hesitancy. The main themes in my talk, whether related to the historical distrust caused by the Tuskegee syphilis research or the battle with Henrietta Lacks’ cells and the progress of cancer treatment without her consent, kept my attention to consciousness. The importance and education of clinical trial participation and its impact on the black community. Many companies, myself included, are committed to driving diversity in the clinical trial workforce and seeking to build trust to encourage more diverse patient participation in clinical trials.
according to Tufts CSDD Study, access to trials, including transportation issues, and a lack of minority clinical researchers are reasons for the lack of participation in the non-white community. That’s why we must have solutions that engage participants in a place they are comfortable and trusted—their own home—to allow clinical trial sponsors and contract research organizations (CROs) to bring trials into the community through technology, Include underserved populations. This helps build a bridge to important evidence for inclusive healthcare solutions.
We have seen evidence that the choice of remote participation matters.in the most recent JAMA In the study, Dr. Jenell Stewart also highlighted the need for new strategies for equitable access and recruitment of diverse clinical trial populations. Stewart found that creating opportunities for remote trial participation is a different maker, noting that “remote trial participation and online recruitment may be associated with improved research equity and inclusion of participants from more diverse racial, ethnic, and geographic communities.”
We also found that trial staffing had an impact on engagement. Ken Getz and his research team also suggested in the Tufts study that locations with high levels of employee diversity are more likely to be located in urban settings with higher numbers of low-income patients and fewer employees. They also noted that patients at these locations were more likely to feel the value of employee diversity. So increase participation. If someone looks like me and asks me to participate in a study, I’m more likely to participate, which could lead to more diverse clinical trial evidence and ultimately life-saving drugs for more patients.
Several industry groups are playing a role to address the lack of patient diversity in clinical trials.This Association of Clinical Research Organizations (ACRO) For example, its members are actively working and committed to increasing the diversity, equity and inclusion of clinical trials. By focusing on four principles and related actions, ACRO’s CROs and technology providers are working to build a clinical research ecosystem that represents the world we live in. These principles include: Improve health equity through access to trials; Empower research partners (patients, sites, HCPs); Collaborate with stakeholders and policy makers; Support and foster relationships with minority health care associations through workforce programs that promote Workforce diversity, equity and inclusion.
In the fight against a global pandemic, we’ve learned a lot about our persistent health inequalities and how we can quickly deliver life-saving solutions to all populations when we work together to overcome existing barriers. We can do it again with the dangerous issue of underrepresentation of black populations in clinical trials. In our scientific community, let us all consciously focus on providing education, building awareness, and bringing the trials themselves into the black community, and doing so with trusted representation among trial staff, restoring trust and Save lives.
Photo: RyanJLane, Getty Images
